Thyrotoxicosis Diagnosis and Titration

The aetiology from TSH, FT4, FT3 and the signs, and the treatment against it · v1

  • Enter the thyroid function tests and the clinical findings.
  • Read High, Normal and Low against your own laboratory's reference ranges, not against a remembered set.
  • Where the free and the total hormone disagree, enter the free value.
  • The numeric fields are optional and are there for the record.
  • You get the causes of thyrotoxicosis separated, and the first drug decisions.

  • Thyroid storm, which is scored at the bedside on the Burch-Wartofsky scale and managed as an emergency.
  • The assessment of a thyroid nodule for malignancy.
  • The choice between radioiodine, surgery and a long course of antithyroid drug, and any radioiodine dose. It names all three and settles none of them.
  • The management of the euthyroid, hypothyroid and hormone-resistance patterns it can label. It names those and sends you back to the symptoms.

1. Biochemical Panel

2. Clinical Exam & Modifiers

3. Investigations & Antibodies

4. Flags That Change the Drug

Clinical Pearls: Thyrotoxicosis

Confirm it biochemically, then find the cause. The second half is where the work is. Destructive thyroiditis mistaken for Graves' disease earns the patient an anti-thyroid drug (ATD) that cannot work on it, for as long as the mistake stands.

1. Total vs. Free Hormones

Total T4 and Total T3 assays measure both bound and unbound hormone. Conditions that increase Thyroid Binding Globulin (TBG), such as pregnancy, oral contraceptive use, and acute hepatitis, will falsely elevate Total T4/T3 levels without causing clinical thyrotoxicosis. Always base therapeutic decisions on Free hormone assays when there is discordance.

2. Graves' Disease, Thyroiditis and the Toxic Nodule

Condition Exam / History TRAb RAIU Scan
Graves' Disease Diffuse goitre, orbitopathy, pretibial myxoedema Positive Diffusely increased uptake
Subacute Thyroiditis Painful, tender goitre; post-viral URI; fever Negative Near-zero / absent uptake
TMNG / Toxic Adenoma Irregular or solitary nodule; older age group Negative Focal or patchy uptake (hot nodules)
Therapeutic Implication: Subacute thyroiditis, silent thyroiditis and Hashitoxicosis release hormone that was already made, from a gland that is being destroyed. Anti-thyroid drugs (Methimazole/Carbimazole) inhibit synthesis, so in these phases there is nothing for them to inhibit. Treat symptomatically with beta-blockers and NSAIDs.

3. Beta-Blocker Selection

Propranolol is the preferred non-selective agent, and at high doses, typically > 160 mg/day, it does a second job: it blocks the peripheral 5'-deiodinase enzyme and prevents conversion of T4 to the more active T3. In asthma or reactive airway disease it is the wrong drug. Use a cardioselective agent there, Atenolol or Metoprolol, and the reason is severe bronchospasm.

4. Anti-Thyroid Drugs (ATDs)

Methimazole / Carbimazole is first-line: once-daily dosing, and a lower risk of fulminant hepatic necrosis. Propylthiouracil (PTU) is kept for two situations and no others. The first trimester of pregnancy, where methimazole carries the embryopathy that includes aplasia cutis. And the acute management of Thyroid Storm, where PTU blocks the peripheral conversion of T4 to T3 as well as synthesis.

Abbreviations AFib (Atrial Fibrillation) · AIT (Amiodarone/Iodine-Induced Thyrotoxicosis) · Anti-TPO (Anti-Thyroid Peroxidase) · ATD (Anti-Thyroid Drug) · BWPS (Burch-Wartofsky Point Scale) · FT3/TT3 (Free/Total Triiodothyronine) · FT4/TT4 (Free/Total Thyroxine) · I-131 (Iodine-131 (Radioactive Iodine)) · IV (Intravenous) · MRI (Magnetic Resonance Imaging) · NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) · PO (Per Os) · PTU (Propylthiouracil) · QID (Four Times Daily) · RAIU (Radioactive Iodine Uptake) · SSKI (Saturated Solution of Potassium Iodide) · T3 (Triiodothyronine) · T4 (Thyroxine) · TBG (Thyroid Binding Globulin) · Tg (Thyroglobulin) · TID (Three Times Daily) · TMNG (Toxic Multinodular Goitre) · TRAb (TSH Receptor Antibody) · TSH (Thyroid Stimulating Hormone) · TSHoma (TSH-Secreting Pituitary Adenoma) · TSI (Thyroid Stimulating Immunoglobulin) · URI (Upper Respiratory Infection) · USG (Ultrasonography)
References
  1. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
  2. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906-918.
  3. Bartalena L, Bogazzi F, Chiovato L, et al. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018;7(2):55-66.
  4. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389.
  5. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22(2):263-277.
  6. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
  7. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905-917.
  8. Unnikrishnan AG, Menon UV. Thyroid disorders in India: an epidemiological perspective. Indian J Endocrinol Metab. 2011;15(Suppl 2):S78-S81.
  9. Unnikrishnan AG, Kalra S, Sahay RK, Bantwal G, John M, Tewari N. Prevalence of hypothyroidism in adults: an epidemiological study in eight cities of India. Indian J Endocrinol Metab. 2013;17(4):647-652.
How to Cite This Tool

DOIhttps://doi.org/10.5281/zenodo.22401653

AMA Style:Umakanth S. Thyrotoxicosis Diagnosis and Titration. Version 1. MEDiscuss Clinical Decision Support System. Published 2026. Accessed . https://mediscuss.org/cdss/thyrotoxicosis-dx. doi:10.5281/zenodo.22401653

Vancouver Style:Umakanth S. Thyrotoxicosis Diagnosis and Titration [Internet]. Version 1. MEDiscuss.org; 2026 [cited ]. Available from: https://mediscuss.org/cdss/thyrotoxicosis-dx. doi:10.5281/zenodo.22401653

Disclaimer and scope
Disclaimer: This decision-support system is written for healthcare professionals. It does not substitute clinical judgment, and the treating physician retains absolute responsibility for every diagnostic, dosing and therapeutic decision. The algorithms are built on the evidence as it stands, and the evidence moves. Verify the output against your current institutional protocol, and against the patient in front of you.
© 2026 MEDiscuss.org. All rights reserved. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Advanced DiagnosticsPathway
Specialties Endocrinology

Written and maintained by

Dr Shashikiran Umakanth

Last revised 24 August 2026

How these tools are written and reviewed

Related Clinical Tools
AF Anticoagulation PathwayGlucocorticoid ConverterPre-Surgical Risk Pathway
Further Reading on MEDiscuss
Hair fall: hope it is telogen effluviumThe reversible shedding that follows a thyroid derangement by three to six months